"The U.S. Food and Drug Administration today approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with skin infections.
Orbactiv is approved to treat patients with acute bacterial skin and skin structure infections (ABSS"...
Cormax Ointment is indicated for short-term treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses. Treatment beyond two consecutive weeks is not recommended, and the total dosage should not exceed 50 g per week because of the potential for the drug to suppress the hypothalamicpituitary-adrenal (HPA) axis.
This product is not recommended for use in pediatric patients under 12 years of age.
DOSAGE AND ADMINISTRATION
A thin layer of Cormax Ointment should be applied with gentle rubbing to the affected skin area twice daily, once in the morning and once at night.
Cormax Ointment is potent; therefore, treatment must be limited to two consecutive weeks, and amounts greater than 50 g per week should not be used. Cormax Ointment is not to be used with occlusive dressings.
Cormax Ointment, 0.05% is supplied in 15 g (NDC 52544-048-86), and 45 g (NDC 52544-048-89) tubes.
Store at controlled room temperature 20-25°C (68-77°F). Do not refrigerate.
Keep out of reach of children.
Manufactured for: Watson Pharmaceuticals, Inc. Corona, CA 92880 USA. Manufactured by: DPT Laboratories, Ltd. San Antonio, TX 78215 USA. Revised: June 2008This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 7/14/2011
Additional Cormax Ointment Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.